INVESTIGADORES
PICHÓN-RIVIERE Andres
artículos
Título:
Bravo pH Monitoring in Gastroesophageal Reflux
Autor/es:
PICHON RIVIERE, A.; AUGUSTOVSKI, F.; GARCIA MARTI, S.; GLUJOVSKY, D.; LOPEZ, A; ALCARAZ, A.; BARDACH, A.; CIAPPONI, A
Revista:
Documento de Evaluación de Tecnologías Sanitarias
Editorial:
IECS
Referencias:
Año: 2013 p. 1 - 30
ISSN:
1668-2793
Resumen:
Gastroesophageal reflux causes a persistent heartburn feeling and/or regurgitation and affects 5-
7% of the population worldwide.
In some selected cases, usually in non responders to drug therapy, it is necessary to monitor
esophageal pH on continued and ambulatory bases. The standard method used for pH monitoring
is the nasogastric tube. To avoid the discomfort produced by the tube, monitoring using the Bravo
capsule has been proposed because it allows a wireless measurement and without the discomfort
caused by the wires.
Technology
The Bravo capsule is a small device containing a radio transmitter, a built-in battery and electrodes
to measure pH. It is placed in the distal end of the esophageal wall through a vacuum pump. This
capsule is wireless and it transmits the pH information collected every 6 seconds to an external
receptor through radiofrequency. Because of the capsule size, it can not be placed through the
nose, but orally. After a 48-96-hour monitoring, the capsule detaches itself from the esophageal
mucosa and it is passed with stools.
Purpose
To assess the available evidence on the efficacy, safety and coverage related aspects regarding
the use of Bravo capsule for pH monitoring in gastroesophageal reflux.
Methods
A bibliographic search was carried out on the main databases: DARE, NHS EED, on Internet
general search engines, in health technology evaluation agencies and health sponsors. Priority
was given to the inclusion of systematic reviews; controlled, randomized clinical trials (RCTs);
health technology assessments and economic evaluations; clinical practice guidelines and
coverage policies of other health systems.
Results
One systematic review, two RCTs, one clinical practice guideline, one HTA and several coverage
policy documents were found.
One systematic review published in 2012 showed that the rate of success in the device placement
and monitoring ranged between 85% and 97%. In seven studies, comparing standard monitoring
with those performed with the wireless device, a good correlation was observed between both
devices in five of them; a similar amount of time with pH